Effect of lenalidomide combined with interferon and interleukin-2 for treatment of refractory/relapsed or minimal residual disease-positive acute myelogenous leukemia
10.3760/cma.j.issn.1009-9921.2019.12.010
- VernacularTitle: 来那度胺联合干扰素及白细胞介素2治疗难治复发或微小残留病阳性急性髓系白血病效果分析
- Author:
Ruihua MI
1
;
Lin CHEN
;
Hao AI
;
Fangfang YUAN
;
Qingsong YIN
;
Xudong WEI
Author Information
1. Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
- Publication Type:Journal Article
- Keywords:
Leukemia, myeloid, acute;
Recurrence;
Refractory;
Minimal residual disease;
Interferons;
Interleukin-2;
Lenalidomide
- From:
Journal of Leukemia & Lymphoma
2019;28(12):743-748
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the efficacy and safety of lenalidomide combined with interferon (IFN) and interleukin-2 (IL-2) for treatment of refractory/relapsed or minimal residual disease (MRD)-positive acute myelogenous leukemia (AML).
Methods:Twelve patients with AML who were hospitalized in the Affiliated Cancer Hospital of Zhengzhou University from August 2013 to May 2019 were selected. These patients were previously treated with thalidomide combined with IFN and IL-2, and then treated with combined with IFN and IL-2. According to the Frence-American-British (FAB) classification system, there was 1 case of M0, 1 case of M1, 4 cases of M2a, 3 cases of M2b, 1 case of M4EO, and 2 cases of M5b. There were 2 cases with FLT3-ITD mutation-positive, 1 case with c-kit mutation-positive. There were 2 cases in the low-risk group, 7 cases in the intermediate-risk group, and 3 cases in the high-risk group. Three cases were refractory AML, 7 cases were relapsed AML (including 3 cases of recurrence once, 4 cases of recurrence twice; 5 cases of recent recurrence, 2 cases of long-term recurrence), 2 cases were MRD-positive. The efficacy and adverse reactions of 12 cases were evaluated.
Results:Twelve patients had received more than one cycle therapy of lenalidomide combined with IFN and IL-2, of which 4 patients achieved morphological complete remission (CR), 2 patients had CR with incomplete recovery of blood cells (CRi), 4 patients had no remission, 1 case had a decrease in MRD, and 1 case had an increase in MRD, and the total effective (CR+ CRi+ partial remission+ MRD decreased) was in 7 cases. There were no adverse reactions such as rash, constipine, bradycardia and peripheral neuritis; six patients had grade Ⅲ or higher experienced myelosuppression. No patients died of complications during the treatment, and the duration of remission of all patients was 2-20 months.
Conclusion:Lenalidomide combined with IFN and IL-2 for treatment of refractory/relapsed or MRD-positive AML is effective, and it can reduce the MRD value in MRD-positive patients, it could be a new treatment method for AML.
